logo-loader

Tetra Bio-Pharma files a PCT patent application for 'Cannabis Plant Residue and Use Thereof'

Published: 08:05 29 Jul 2021 EDT

Cannabis plant
GRAS status will allow for the broad application of this novel ingredient in foods as well as dietary supplements

Tetra Bio-Pharma (TSX:TBP, OTCQB:TBPMF) Inc. said it has filed a PCT patent application for 'Cannabis Plant Residue and Use Thereof', under PCT Patent Application No. PCT/CA2021/050886, with a filing date of June 28, 2021.

Through Tetra's partnership with Thorne HealthTech, a submission to the US Food and Drug Administration (FDA) for Generally Recognized as Safe (GRAS) is being pursued. GRAS status will allow for the broad application of this novel ingredient in foods as well as dietary supplements.

READ: Tetra Bio-Pharma welcomes Christine Caron as a patient partner in its sepsis research

Research conducted through Tetra has shown that cannabis plant residue can increase the growth of beneficial gut microbes including both Lactobaccillus rhamnosus and Bifidobacterium longum. When compared against the industry standard inulin, Tetra's findings suggest this previously considered "waste material" to be discarded after cannabinoid extraction, as an excellent candidate for use as a novel prebiotic supplement.

If granted, this patent application Tetra said will provide it with protection for the use of cannabis plant residue material containing residual cannabinoids within a specified profile range, as an oral prebiotic component alone or in combination with other pro, post, para, or prebiotics as a dietary supplement for gastrointestinal health.

Tetra Bio-Pharma is a leader in cannabinoid-derived drug discovery and development with an FDA and a Health Canada cleared clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers.

Its evidence-based scientific approach has enabled us to develop a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing biopharma industry by regulators, physicians and insurance companies.

Contact the author at jon.hopkins@proactiveinvestors.com

Tetra Bio-Pharma updates on progress made with inhaled cannabinoid-based...

Tetra Bio-Pharma (TSX:TBP, OTCQB:TBPMF) Inc. Guy Chamberland talks to Proactive about the significance of the response letter for a Type C meeting with the FDA for its inhaled cannabinoid-based product, QIXLEEF. Chamberland says the FDA has given the group clear guidance, which will allow Tetra...

on 03/30/2022